FREDUN PHARMACEUTICALS LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 846 INR | +1.22% |
|
-6.11% | -2.62% |
| May. 08 | Fredun Pharmaceuticals' Net Profit Jumps in Fiscal Q4; Shares Dip 9% | MT |
| May. 07 | Fredun Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 2.24B 26.89M | Sales 2023 | 2.75B 32.91M | Capitalization | 3.57B 42.8M |
|---|---|---|---|---|---|
| Net income 2022 | 63M 755K | Net income 2023 | 108M 1.29M | EV / Sales 2022 | 2.07 x |
| Net Debt 2022 | 586M 7.02M | Net Debt 2023 | 831M 9.96M | EV / Sales 2023 | 1.6 x |
| P/E ratio 2022 |
64.1
x | P/E ratio 2023 |
32.2
x | Employees | 260 |
| Yield 2022 |
0.08% | Yield 2023 |
0.09% | Free-Float | 41.59% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.06% | ||
| 1 week | -5.33% | ||
| Current month | -8.83% | ||
| 1 month | +5.06% | ||
| 3 months | +4.94% | ||
| 6 months | -2.70% | ||
| Current year | -1.81% |
1 week
820.00
1 024.00
1 month
752.001 024.00
Current year
650.001 054.00
1 year
650.001 249.00
3 years
351.201 428.00
5 years
103.001 428.00
10 years
12.501 428.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 37 | 06-09-14 | |
| Chief Executive Officer | 79 | 87-06-07 | |
Jinkal Shah
CMP | Compliance Officer | - | 22-01-27 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 79 | 87-06-07 | |
| Director/Board Member | 54 | 15-05-29 | |
| Director/Board Member | 75 | 15-09-29 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 846 | +1.22% | 978 |
| 24-05-09 | 835.8 | -7.67% | 22,926 |
| 24-05-08 | 905.2 | -9.69% | 28,257 |
| 24-05-07 | 1,002 | +2.11% | 34,085 |
| 24-05-06 | 981.6 | +8.95% | 50,635 |
Delayed Quote Bombay S.E., May 10, 2024 at 12:12 am EDT
More quotes
Fredun Pharmaceuticals Ltd. is an India-based pharmaceutical company. The Company is primarily engaged in the business of pharmaceuticals and healthcare. The Company operates through four segments: Generics (Exports & Fredun Gx), Pet Healthcare (Freossi), Nutraceuticals (Fredun Nutrition) and Cosmeceuticals (Bird and Beauty or BnB). It offers a range of products, including antihypertensive, antidiabetic, antiretroviral drugs (ARVs) and narcotics. It is also engaged in the manufacturing of dietary /herbal supplements, nutraceuticals, and other healthcare products along with animal healthcare products. The Company primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America.
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -1.81% | 50.99M | |
| +32.36% | 698B | |
| +26.51% | 568B | |
| -4.40% | 358B | |
| +19.46% | 328B | |
| +3.50% | 283B | |
| +16.34% | 238B | |
| +6.68% | 203B | |
| -9.08% | 198B | |
| +8.62% | 165B |
- Stock Market
- Equities
- FREDUN6 Stock